Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion

被引:2
作者
Lutfi, Forat [1 ]
Bishnoi, Rohit [2 ]
Patel, Vikas [3 ]
Elfasi, Aisha [4 ]
Setteducato, Michael [3 ]
Zhang, Shuyao [5 ]
Shah, Chintan P. [2 ]
Kurian, Saji [3 ]
Kamath, Chethana [3 ]
Kim, Dae Jun [3 ]
Zumberg, Marc S. [2 ]
Murphy, Martina [2 ]
机构
[1] Univ Maryland, Med Ctr, Hematol & Oncol, Baltimore, MD 21201 USA
[2] Univ Florida Hlth, Hematol & Oncol, Gainesville, FL USA
[3] Univ Florida Hlth, Internal Med, Gainesville, FL USA
[4] Univ Florida Hlth, Neurol, Gainesville, FL USA
[5] Univ Texas Southwestern Med Ctr Dallas, Internal Med, Dallas, TX 75390 USA
关键词
anticoagulant therapy; heparin; thrombosis; hemorrhage; venous thromboembolism; MONITORING UNFRACTIONATED HEPARIN; PARTIAL THROMBOPLASTIN TIME; ANTITHROMBOTIC THERAPY; ATRIAL-FIBRILLATION; DOSING NOMOGRAM; ASSAY;
D O I
10.7759/cureus.8339
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intravenous unfractionated heparin (UFH) remains one of the most commonly used anticoagulants in the hospital setting. The optimal protocol for initiation and maintenance of UFH has been difficult to determine. Over the past two decades, weight-based nomogram protocols have gained favor. Herein, we present a retrospective study of 377 patients at a single tertiary academic center treated with low intensity (LI) and standard intensity (SI) UFH protocols for therapeutic anticoagulation. UFH levels are measured by anti-Xa assay activity with therapeutic levels of 0.30 to 0.70 IU/mL for SI and 0.25 to 0.35 IU/mL for LI. Patients treated on the LI protocol were more likely to have had a previous history of bleeding and lower baseline hemoglobin. Incidence of new or worsening thrombus while on UFH was comparable between both protocols (odds ratio (OR) 0.93, 95% confidence interval (CI) 0.29-2.98, p=0.899). Patients on LI protocol had higher incidence of bleeding while on UFH (OR 1.21, 95% CI 0.51-2.89, p=0.667). Our study thus suggests that the LI protocol may have comparable efficacy to the SI protocol in treating venous thromboembolism (VTE) and that target anti-Xa levels of 0.25 to 0.35 IU/mL may be more optimal in high-risk patients.
引用
收藏
页数:11
相关论文
共 28 条
[1]   ESTABLISHING A THERAPEUTIC RANGE FOR HEPARIN-THERAPY [J].
BRILLEDWARDS, P ;
GINSBERG, JS ;
JOHNSTON, M ;
HIRSH, J .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) :104-109
[2]   Antithrombotic therapy for venous thromboembolic disease [J].
Büller, HR ;
Agnelli, G ;
Hull, RD ;
Hyers, TA ;
Prins, AH ;
Raskob, GE .
CHEST, 2004, 126 (03) :401S-428S
[3]   A STANDARD HEPARIN NOMOGRAM FOR THE MANAGEMENT OF HEPARIN-THERAPY [J].
CRUICKSHANK, MK ;
LEVINE, MN ;
HIRSH, J ;
ROBERTS, R ;
SIGUENZA, M .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (02) :333-337
[4]  
Francis JL, 2004, PHARMACOTHERAPY, V24, P108
[5]   Prevention of venous thromboembolism [J].
Geerts, WH ;
Pineo, GF ;
Heit, JA ;
Bergqvist, D ;
Lassen, MR ;
Colwell, CW ;
Ray, JG .
CHEST, 2004, 126 (03) :338S-400S
[6]   Activated Partial Thromboplastin Time Versus Antifactor Xa Heparin Assay in Monitoring Unfractionated Heparin by Continuous Intravenous Infusion [J].
Guervil, David J. ;
Rosenberg, Amy F. ;
Winterstein, Almut G. ;
Harris, Neil S. ;
Johns, Thomas E. ;
Zumberg, Marc S. .
ANNALS OF PHARMACOTHERAPY, 2011, 45 (7-8) :861-868
[7]   Executive Summary Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Guyatt, Gordon H. ;
Akl, Elie A. ;
Crowther, Mark ;
Gutterman, David D. ;
Schuenemann, Holger J. .
CHEST, 2012, 141 (02) :7S-47S
[8]   Introduction to the Ninth Edition Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Guyatt, Gordon H. ;
Akl, Elie A. ;
Crowther, Mark ;
Schuenemann, Holger J. ;
Gutterman, David D. ;
Lewis, Sandra Zelman .
CHEST, 2012, 141 (02) :48S-52S
[9]   CONTINUOUS INTRAVENOUS HEPARIN COMPARED WITH INTERMITTENT SUBCUTANEOUS HEPARIN IN THE INITIAL TREATMENT OF PROXIMAL-VEIN THROMBOSIS [J].
HULL, RD ;
RASKOB, GE ;
HIRSH, J ;
JAY, RM ;
LECLERC, JR ;
GEERTS, WH ;
ROSENBLOOM, D ;
SACKETT, DL ;
ANDERSON, C ;
HARRISON, L ;
GENT, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (18) :1109-1114
[10]  
HYERS TM, 1989, CHEST, V95, pS37, DOI 10.1378/chest.95.2_Supplement.37S